188 related articles for article (PubMed ID: 12631372)
1. Depolymerized holothurian glycosaminoglycan (DHG), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model.
Minamiguchi K; Kitazato KT; Nagase H; Sasaki E; Ohwada K; Kitazato K
Kidney Int; 2003 Apr; 63(4):1548-55. PubMed ID: 12631372
[TBL] [Abstract][Full Text] [Related]
2. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
[TBL] [Abstract][Full Text] [Related]
3. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
[TBL] [Abstract][Full Text] [Related]
4. DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low molecular weight heparin, in rats.
Kitazato K; Kitazato KT; Nagase H; Minamiguchi K
Thromb Res; 1996 Oct; 84(2):111-20. PubMed ID: 8897700
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka.
Suzuki N; Kitazato K; Takamatsu J; Saito H
Thromb Haemost; 1991 Apr; 65(4):369-73. PubMed ID: 1647552
[TBL] [Abstract][Full Text] [Related]
6. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice.
Nagase H; Kitazato KT; Sasaki E; Hattori M; Kitazato K; Saito H
Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603
[TBL] [Abstract][Full Text] [Related]
7. Neutralization of DHG, a new depolymerized holothurian glycosaminoglycan, by protamine sulfate and platelet factor 4.
Sasaki E; Minamiguchi K; Kitazato KT; Nagase H; Kitazato K
Haemostasis; 1997; 27(4):174-83. PubMed ID: 9483172
[TBL] [Abstract][Full Text] [Related]
8. Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin.
Nagase H; Enjyoji K; Minamiguchi K; Kitazato KT; Kitazato K; Saito H; Kato H
Blood; 1995 Mar; 85(6):1527-34. PubMed ID: 7888673
[TBL] [Abstract][Full Text] [Related]
9. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
10. Interaction of a new depolymerized holothurian glycosaminoglycan with proteins in human plasma.
Minamiguchi K; Nagase H; Kitazato KT; Kitazato K
Thromb Res; 1996 Aug; 83(3):253-64. PubMed ID: 8840467
[TBL] [Abstract][Full Text] [Related]
11. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H
Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
13. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
14. Structure and anticoagulant activity of fucosylated glycosaminoglycan degraded by deaminative cleavage.
Zhao L; Lai S; Huang R; Wu M; Gao N; Xu L; Qin H; Peng W; Zhao J
Carbohydr Polym; 2013 Nov; 98(2):1514-23. PubMed ID: 24053834
[TBL] [Abstract][Full Text] [Related]
15. Dermatan sulfate: an alternative to unfractionated heparin for anticoagulation in hemodialysis patients.
Vitale C; Berutti S; Bagnis C; Soragna G; Gabella P; Fruttero C; Marangella M
J Nephrol; 2013; 26(1):158-63. PubMed ID: 22419236
[TBL] [Abstract][Full Text] [Related]
16. Effect of depolymerized holothurian glycosaminoglycan (DHG) on the activation of factor VIII and factor V by thrombin.
Nagase H; Enjyoji K; Shima M; Kitazato K; Yoshioka A; Saito H; Kato H
J Biochem; 1996 Jan; 119(1):63-9. PubMed ID: 8907177
[TBL] [Abstract][Full Text] [Related]
17. Depolymerized glycosaminoglycan and its anticoagulant activities from sea cucumber Apostichopus japonicus.
Yang J; Wang Y; Jiang T; Lv L; Zhang B; Lv Z
Int J Biol Macromol; 2015 Jan; 72():699-705. PubMed ID: 25260572
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs.
Choi JH; Byun SY; Nam A; Han SM; Lee KP; Song KH; Youn HY; Seo KW
J Vet Emerg Crit Care (San Antonio); 2018 Mar; 28(2):122-129. PubMed ID: 29419934
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
[TBL] [Abstract][Full Text] [Related]
20. The safety of heparins in end-stage renal disease.
Sonawane S; Kasbekar N; Berns JS
Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
